Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury KI, Thompson PA, Burke G, Bressel M, Di Iulio JL, Hicks RJ, Westerman DA, Lade S, Pott C, Agarwal R, Koldej RM, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Handunnetti SM, et al. Among authors: lade s. Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388. Online ahead of print. Blood. 2024. PMID: 38662991
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Di Iulio J, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA, Seymour JF, Roberts AW. Tam CS, et al. Among authors: lade s. N Engl J Med. 2018 Mar 29;378(13):1211-1223. doi: 10.1056/NEJMoa1715519. N Engl J Med. 2018. PMID: 29590547 Free article. Clinical Trial.
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study.
Minson A, Hamad N, Cheah CY, Tam C, Blombery P, Westerman D, Ritchie D, Morgan H, Holzwart N, Lade S, Anderson MA, Khot A, Seymour JF, Robertson M, Caldwell I, Ryland G, Saghebi J, Sabahi Z, Xie J, Koldej R, Dickinson M. Minson A, et al. Among authors: lade s. Blood. 2024 Feb 22;143(8):673-684. doi: 10.1182/blood.2023021306. Blood. 2024. PMID: 37883795 Clinical Trial.
Prospective Phase II trial of radiation therapy in localised non-gastric marginal zone lymphoma with prospective evaluation of autoimmunity and Helicobacter pylori status: TROG 05.02/ALLG NHL15.
MacManus MP, Roos D, O'Brien P, Capp A, Wirth A, Tsang R, Bressel M, Lade S, Seymour JF. MacManus MP, et al. Among authors: lade s. Eur J Cancer. 2021 Jul;152:129-138. doi: 10.1016/j.ejca.2021.05.004. Epub 2021 Jun 5. Eur J Cancer. 2021. PMID: 34098462 Clinical Trial.
Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target.
Gould C, Lickiss J, Kankanige Y, Yerneni S, Lade S, Gandhi MK, Chin C, Yannakou CK, Villa D, Slack GW, Markham JF, Tam CS, Nelson N, Seymour JF, Dickinson M, Neeson PJ, Westerman D, Blombery P. Gould C, et al. Among authors: lade s. Br J Haematol. 2021 Oct;195(1):113-118. doi: 10.1111/bjh.17789. Epub 2021 Aug 23. Br J Haematol. 2021. PMID: 34426978
117 results